Literature DB >> 29229267

Intracavitary Contrast-Enhanced Ultrasound in the Management of Post-Surgical Gastrointestinal Fistulas.

Er-Jiao Xu1, Man Zhang1, Kai Li1, Zhong-Zhen Su1, Ying-Lin Long1, Qing-Jin Zeng1, Huan-Yi Guo1, Rong-Qin Zheng2.   

Abstract

The goal of this study was to investigate intracavitary contrast-enhanced ultrasound (IC-CEUS) measures in the management of post-surgical gastrointestinal (GI) fistula throughout detection, treatment and follow-up. From June 2010 to August 2016, patients who were administered ultrasound contrast agent (UCA) via a drainage tube for IC-CEUS were enrolled and retrospectively analyzed. They were suspected of having GI anastomotic fistulas or had been found to have fluid collections with ultrasound that were accompanied by abdominal pain or fever after surgical procedures. Forty-two patients met the inclusion criteria and were enrolled into this study. Twenty-two were confirmed to have GI fistulas confirmed by standard references. None were detected by conventional ultrasound. Although IC-CEUS successfully detected GI fistulas in 16 patients, it missed GI fistulas in 6 patients. One patient was misdiagnosed with a GI fistula. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the diagnosis of GI fistulas by IC-CEUS were 72.7% (16/22), 95.0% (19/20), 94.1% (16/17), 76.0% (19/25) and 83.3% (35/42), respectively. Twenty peritoneal fluid collections in 14 patients were related to fistulas by IC-CEUS based on the distribution of ultrasound contrast agents. Additional drainage was performed in 14 fistula-related fluid collections. Eight GI fistulas were judged to be cured after IC-CEUS re-evaluation, and the drainage tubes were removed from these patients. In conclusion, IC-CEUS can greatly improve the ability to diagnose post-surgical GI fistulas and may also play an important role in interventional treatment and follow-up.
Copyright © 2018 World Federation for Ultrasound in Medicine and Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast-enhanced ultrasound; Gastrointestinal fistula; Management; Ultrasound

Mesh:

Substances:

Year:  2017        PMID: 29229267     DOI: 10.1016/j.ultrasmedbio.2017.10.012

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  5 in total

Review 1.  Intracavitary contrast-enhanced ultrasonography in children: review with procedural recommendations and clinical applications from the European Society of Paediatric Radiology abdominal imaging task force.

Authors:  Damjana Ključevšek; Michael Riccabona; Lil-Sofie Ording Müller; Magdalena Maria Woźniak; Stéphanie Franchi-Abella; Kassa Darge; Hans-Joachim Mentzel; Aikaterini Ntoulia; Fred Efraim Avni; Marcello Napolitano; Luisa Lobo; Annemieke Simone Littooij; Thomas Angell Augdal; Costanza Bruno; Beatrice Maria Damasio; Donald Ibe; Samuel Stafrace; Philippe Petit
Journal:  Pediatr Radiol       Date:  2020-02-13

2.  Anthracycline Treatment and Left Atrial Function in Children: A Real-Time 3-Dimensional Echocardiographic Study.

Authors:  Dipika Menon; Gilda Kadiu; Yamuna Sanil; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2021-11-17       Impact factor: 1.655

3.  The Value of Contrast-Enhanced Ultrasound-Guided Contrast Injection via the Endoscopic Nasobiliary Drainage Duct in Diagnosing Residual Common Bile Duct Stones.

Authors:  Yang Wang; Yue Yang; Kaiming Wang; Shaoshan Tang
Journal:  Biomed Res Int       Date:  2020-07-01       Impact factor: 3.411

4.  Application Value of Contrast-Enhanced Ultrasound Combined with Enhanced MR Scanning in Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Mingming Zhang; Yan Liu; Lei Han; Guixiang Zhang
Journal:  J Healthc Eng       Date:  2022-03-31       Impact factor: 2.682

5.  Evaluation of Cardiac Space-Occupying Lesions by Myocardial Contrast Echocardiography and Transesophageal Echocardiography.

Authors:  Mingming Ren; Lei Huang; Xiaoqiang Ye; Zhifeng Xv; Chun Ouyang; Zhen Han
Journal:  J Healthc Eng       Date:  2022-01-25       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.